Table 3 Antimicrobial resistance patterns of critical pathogens of bloodstream infections
E. coli | K. pneumoniae | A. baumannii | P. aeruginosa | S. aureus | |
|---|---|---|---|---|---|
No. isolates | 1915 | 696 | 133 | 135 | 681 |
No. isolates with ASTa | 1820 | 643 | 123 | 121 | 640 |
MDRb | 49.5 (901/1820) | 15.6 (100/643) | 46.3 (57/123) | 18.2 (22/121) | 75.6 (484/640) |
MDR CA-BSIc | 48.4 (789/1631) | 10.7 (55/516) | 15.3 (6/39) | 4.8 (3/63) | 73.9 (383/518) |
MDR HA-BSIc | 61.4 (105/171) | 36.9 (45/122) | 60.7 (51/84) | 34.5 (19/55) | 82.4 (98/119) |
Gentamicind | 30.6 (232/758) | 11.4 (31/272) | 32.8 (19/58) | 14.3 (16/112) | -e |
Amikacin | 1.2 (13/1102) | 1.9 (8/414) | 31.1 (32/103) | 19.3 (23/119) | - |
Piperacillin/tazobactam | 6.3 (114/1815) | 7.5 (48/640) | 43.9 (54/123) | 6.8 (8/118) | - |
Ceftriaxone | 56.1 (1013/1805) | 14.4 (91/633) | - | - | - |
Ceftazidime | 54.8 (805/1470) | 16 (83/519) | 49.6 (60/121) | 11.6 (14/121) | - |
Cefepime | 47.4% (853/1799) | 12.6 (79/628) | 49.2 (60/122) | 19.5 (23/118) | - |
Ertapenem | 1.2 (22/1791) | 4.4 (27/619) | - | - | - |
Imipenem | 0.6 (11/1794) | 3.8 (24/629) | 42.3 (52/123) | 11.7 (14/120) | - |
Meropenem | 0.6 (10/1630) | 4.7 (27/576) | 43.9% (54/123) | 11.8 (14/119) | - |
Colistin | 0 (0/26) | 11.1 (3/27) | 0.8 (1/118) | 0 (0/78) | - |
Trimethoprim/sulfamethoxazole | 64.5 (1048/1624) | 25.9 (156/602) | 38.2 (42/110) | - | 16.1 (79/492) |
Ciprofloxacin | 52.4% (676/1290) | 22.2 (101/455) | 39 (32/82) | 20.4 (19/93) | 37.8 (235/621) |
Levofloxacin | 52.6% (545/1036) | 12.8 (46/359) | 42.7 (44/103) | 20.6 (22/107) | 32.8 (171/521) |
Moxifloxacin | - | - | - | - | 26 (26/100) |
Benzylpenicillin | - | - | - | - | 98 (623/636) |
Oxacillin | - | - | - | - | 58.2 (370/636) |
Erythromycin | - | - | - | - | 71.9 (447/622) |
Clindamycin | - | - | - | - | 69.6 (436/626) |
Rifampicin | - | - | - | - | 3.8 (24/637) |
Vancomycin | - | - | - | - | 0 (0/633) |
Teicoplanin | - | - | - | - | 0.4 (1/262) |
Linezolid | - | - | - | - | 0 (0/288) |
